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ABSTRACT
Introduction: Adverse drug reactions (ADRs) are threat to the patient’s safety and the quality of life, and 
they increase the cost of health care. Spontaneous ADR reporting system mainly relies on physicians, but 
also pharmacists, nurses, and even patients. The aim of this study was to explore attitudes, barriers, and 
possible improvements to ADR reporting practices in Bosnia and Herzegovina.
Methods: A self-reported questionnaire was developed to collect data on the perception of pharma-
covigilance practice and ADR reporting. The survey was conducted in the period between September, 
2014 and October, 2014.
Results: The response rate was 73% (44 of 60) and 93% (148 of 160) among the pharmacist and 
family medicine physician groups, respectively. Regarding the attitudes to pharmacovigilance practice 
and reporting, both the pharmacists and physicians found the practices important. The majority of phar-
macists and physicians in year 2014 did not report any ADR, while 18% of the pharmacists and 12% of 
the physicians, who participated in this study, reported one ADR. Reporting procedure, uncertainty, and 
their exposure were the main barriers to reporting ADRs for the pharmacists. The physicians claimed lack 
of knowledge to whom to report an ADR as the main barrier. A significant number of the respondents 
thought that additional education in ADR reporting would have a positive impact, and would increase 
the ADR reporting rate.
Conclusions: Despite the overall positive attitude towards ADR reporting, the reporting rate in Bosnia 
and Herzegovina is still low. Different barriers to the ADR reporting have been identified, and there is also 
the need for improvements in the traditional education in this field.
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INTRODUCTION
Pharmacovigilance (PV) is defined by the World 
Health Organization (WHO) as “the science 
and activities relating to the detection, assess-
ment, understanding and prevention of adverse 
effects or any other drug-related problem“ (1). 
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After thalidomide disaster in 1961, the WHO 
established the Program for International Drug 
Monitoring.
Adverse drug reactions (ADRs) are threat to a 
patient’s safety and the quality of life. In addition, 
they increase the health care costs considerably. 
ADRs are one of the leading causes of mortality and 
morbidity (2,3). It was estimated that around 2.9% 
to 5.6% of all hospital admissions are due to ADRs, 
and 35% of hospitalized patients experience an 
ADR during their hospitalization (4). The economic 
burden of ADR is also considerable. For example, in 
the United States $47.4 billion was reported as the 
annual total cost for 8.7 million drug related admis-
sions (5). The Uppsala Monitoring Centre (UMC), 
located in Uppsala, Sweden, is the field name for the 
World Health Organization Collaborating Centre 
for International Drug Monitoring. The UMC 
works by collecting, assessing, and communicating 
information from member countries’ national pro-
grams in regard to the benefits, harm, effectiveness, 
and risks of drugs.
Pharmacovigilance system was established in Bosnia 
and Herzegovina at the national level in 2008, when 
the Agency for Medicines and Medical Devices 
(ALIMSBiH) was initiated for collecting the 
ADR reports and providing information on ADR. 
Pharmacovigilance was introduced into the phar-
maceutical legislation of Bosnia and Herzegovina, 
representing a mandatory activity for healthcare 
professionals, manufacturers, and marketing autho-
rization holders (6,7).
The foundation of the International Society of 
Pharmacoepidemiology (ISPE) in 1984 and of the 
European Society of Pharmacovigilance (ESOP 
– later ISoP – the International Society) in 1992, 
marked formally the introduction of pharmacovigi-
lance into the research and academic community, as 
well as its increasing integration into clinical prac-
tice (8). A national pharmacovigilance system is the 
primary way to collect the information on ADR 
practices, in both hospital and community settings. 
The effectiveness and success of any pharmacovigi-
lance system depend highly on the participation of 
all healthcare professionals and the degree of co-op-
eration and communication between practitioners 
and a pharmacovigilance center.
Spontaneous reporting is an important tool in 
pharmacovigilance. However, its success depends 
on cooperative and motivated prescribers (9). 
Although physicians, pharmacists, dentists, and 
nurses play a key role in pharmacovigilance pro-
grams (10,11), underreporting is very common, 
with an estimated median rate of 94% (the 
median rate is defined as the percentage of ADRs 
detected in extensive data collection that were 
not reported to relevant spontaneous reporting 
systems). Even though most countries have estab-
lished systems for spontaneous ADR reporting, 
they still face low reporting rates by health care 
professionals (12).
In most countries, including Bosnia and 
Herzegovina, the spontaneous ADR reporting sys-
tem mainly targets physicians as the major source 
for reporting. Nevertheless, there is an increas-
ing trend in ADR reporting by hospital pharma-
cists, community pharmacists, nurses, and even 
patients (13-15).
Numerous studies have been conducted in order 
to assess the attitudes of health care practitioners 
towards their national ADR reporting pro-
grams, identifying different reasons for underre-
porting (16-18).
The aim of this study was to assess the knowledge 
and awareness of ADR reporting and pharmacovig-
ilance system among healthcare professionals in 
Bosnia and Herzegovina. We analyzed attitudes, 
barriers, and possible improvements from the per-
spective of pharmacists and physicians at the pri-
mary care level.
METHODS
For this cross-sectional study, a self-reported ques-
tionnaire was developed. Demographic and data 
related to the perception of pharmacovigilance prac-
tice, previous reporting experience and attitudes of 
community pharmacists and family medicine physi-
cians were collected. Among the pharmacist group, 
the questionnaires were distributed and collected 
during a pharmacists’ continuing education course, 
held in October 2014. The survey of the family 
medicine physicians was performed during educa-
tion courses, held in September 2014 and October 
2014. All of the surveyed individuals received an 
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explanation of why the survey was being conducted 
and that only fully answered questionnaires will be 
valid for the analysis.
The survey questions were based on previously con-
ducted studies with slight adaptations to the local 
practices. Each questionnaire consisted of four 
parts; A – demographic characteristics, B – attitudes, 
C – barriers to reporting ADRs, and D – factors that 
could improve current practices. The questionnaire 
comprised of 25 questions: 5 related to the sec-
tion A, covering demographic, education, and work 
experience; 8 questions in the section B with multi-
ple choice answers; 7 in the section C, and 5 in the 
section D, with dichotomous questions.
Statistical analysis
Statistical analyses were performed using MedCalc 
for Windows, version  12.6 (MedCalc Software, 
Ostend, Belgium). p < 0.05 was considered statis-
tically significant.
RESULTS
The response rate was 73% (44 of 60) among the 
pharmacist group and 93% (148 of 160) among 
the family medicine physician group. The demo-
graphic and professional details of the respondents 
are shown in Table 1. The Chi-square test showed 
no significant difference in work experience between 
the pharmacists and physicians (X2 = 5.644, df = 
5.644; p = 0.1302).
Regarding attitudes to pharmacovigilance practice 
and reporting, both the pharmacists and physicians 
found the activities important. A detail overview of 
the current ADR reporting practice attitudes by the 
pharmacists and physicians is presented in Table 2.
In the second part of the questionnaire, barriers to 
the ADR reporting were identified. The responses 
are presented in Table 3. We found statistically sig-
nificant differences between the pharmacists and 
physicians in terms of the most common reasons for 
not reporting ADR (X2 = 45.424, p < 0.0001) and 
TABLE 1. Demographic and professional details of the respondents
N (%) Chi‑square Significance 
level (p)Pharmacists Physicians 
Total 148 (100) 44 (100)
Sex
Male 13 (8.8) 14 (31.8) 13.046 0.0003*
Female 135 (91.2) 30 (68.2)
Age (years)
24‑30 45 (30.4) 2 (4.6) 12.517 0.0019*
31‑41 36 (24.3) 13 (29.5)
>40 67 (45.3) 29 (65.9)
Work experience (years)
<1 21 (14.6) 3 (6.8) 5.644 0.1302*
1‑5 34 (23) 5 (11.4)
6‑10 16 (10.1) 7 (15.9)
>10 77 (52.3) 29 (65.9)
Level of education
Graduate 141 (95.3) 10 (22.7) 108.004 <0.0001*
Specialization 4 (2.7) 28 (63.6)
Postgraduate 3 (2) 6 (13.7)
Work environment
Community pharmacy 125 (84.5) 0 (0) 6.364 0.0116
Hospital pharmacy 23 (15.5) 0 (0)
Primary care practice 0 (0) 44 (100)
Hospital care practice 0 (0) 0 (0)
*Statistically significant
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in terms of information on where to find the official 
ADR reporting form (Chi2 (3, n = 192) = 44.361, 
p < 0.0001). The pharmacists mainly reported that 
they are not familiar with the ADR reporting pro-
cedure, they are afraid of wrong reporting, and that 
they do not want to expose themselves. The main 
reason among the physicians was lack of informa-
tion on whom to report ADR. The majority of the 
respondents from both groups quote that an ADR 
reporting form could be found on the Internet. The 
highest difference between the groups related to the 
source of ADR reporting form was that the phar-
macists chose the National Drug Registry, published 
annually by the Agency for medicines and medical 
devices in the form of a printed book, while the 
physicians preferred other sources.
The attitudes towards activities that could improve 
the ADR reporting were examined in the third 
part of the questionnaire. A  detail analysis of the 
responds is presented in Table 4.
Based on the Chi-square test, a significant difference 
was observed between the two groups, regarding 
whether the ADR reporting should be recognized 
by the professional chambers, and evaluated as a 
part of continuing education (Chi2 (1, n = 192) = 
9.901, p = 0.0017). Also, a difference between the 
groups was identified in the case of possible simpli-
fication of the current reporting process (Chi2  (1, 
n = 192) = 7.119, p = 0.0076). The majority of 
the pharmacists (48%) considered that e-reporting 
through a website could improve the ADR report-
ing practice, and 35% of the physicians followed 
this option. The majority of the respondents from 
each group (51%) think that the current written 
reporting practice should be kept. Fifty-five percent 
of the pharmacists and 66% of the physicians con-
sidered that additional education in ADR reporting 
would have a positive impact and thus increase the 
ADR reporting rate.
DISCUSSION
This is the first survey based research on the cur-
rent practices in ADR reporting in Bosnia and 
Herzegovina. The survey compared the attitudes of 
pharmacists and physicians towards this issue.
The pharmacists considered ADR reporting as a 
legal obligation in the first place, and then as a pro-
fessional obligation, while the physicians equally 
ranked these questions. Both groups ranked ethical 
obligation at the same level. The attitudes to whose 
obligation is to report ADR were divided. The phar-
macists considered that they are the first obliged to 





Professional obligation 78 (37) 21 (36)
Legal obligation 81 (39) 21 (36)
Ethical Obligation 51 (24) 17 (24)
I believe that ADR reporting is 
important
Yes 147 (99) 44 (100)
No 1 (1) 0 (0)
ADR reporting is obligation for
Physicians 49 (19) 38 (58)
Pharmacists 123 (48) 9 (14)
Industry 42 (16) 9 (14)
Patients 42 (16) 10 (15)
ADR reporting is not mandatory
Agree 8 (5) 1 (2)
Disagree 140 (95) 43 (98)
In last year I have reported
Non ADR 126 (85) 32 (73)
1 ADR 18 (12) 8 (18)
2‑5 ADRs 3 (2) 2 (5)
>5 ADRs 1 (1) 2 (5)
ADR should be reported to
Professional association 11 (6) 1 (2)
Agency for medicines and 
medical devices
134 (76) 40 (78)
Manufacturer 18 (10) 7 (14)
Health/pharmaceutical 
inspectorate
4 (2) 2 (4)
Ministry of health 9 (5) 1 (2)
ADR related to OTC drugs 
should not be reported
Agree 7 (5) 2 (5)
Disagree 141 (95) 42 (95)
Before ADR reporting I should 
consult with physician/pharmacist
Agree 38 (26) 10 (23)
Disagree 110 (74) 34 (77)
ADR=Adverse drug reaction
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report, while the physicians found that the obliga-
tion is in their jurisdiction. Both groups had similar 
attitudes towards drug manufacturers and patients. 
A similar percentage of the respondents did not see 
the need to consult with each other (the pharma-
cist with physician and vice versa) before report-
ing ADR. The Chi-square test showed that there 
is a significant difference between the pharmacists 
and physicians with regard to the attitudes towards 
whose obligation is to report ADRs (Chi2  (3, 
n  =  192) = 44.151, p < 0.0001). Both groups of 
the healthcare professionals considered the Agency 
for medicines and medical devices of Bosnia and 
Herzegovina as the address to report ADR, which 
is correct and defined by the current legislation. 
They also considered other institutions for reporting 
ADR, such as professional associations, the Ministry 
of Health, and the manufacturers. The majority of 
the pharmacists and physicians did not report any 
ADR in 2014 year. Eighteen percent of the pharma-
cists and 12% of the physicians, who participated in 
this study, reported one ADR.
Even though ALIMSBIH launched pharma-
covigilance department and reporting in 2009, 
the reporting level is still too low, especially com-
pared to the number of adverse reactions reported 
TABLE 3. Barriers and knowledge of ADR reporting reported by the pharmacists and physicians
Barriers to ADR reporting N (%) Chi‑square Significance 
level (p)Pharmacists Physicians
Most common reasons for not reporting ADR
Do not know whom to report ADR 8 (5.5) 18 (37.5) 45.424 <0.0001*
I do not know ADR reporting procedure 49 (34) 17 (35.4)
I am afraid of wrong report and personal discredit 30 (20.8) 0 (0)
Reporting form is complicated 17 (11.8) 6 (12.5)
I have no time for ADR reporting 19 (13.2) 7 (14.6)
I do not want to expose myself 21 (14.7) 0 (0)
ADR reporting form can be found at
Internet site 72 (40.7) 10 (22.7) 44.361 <0.0001*
Official gazette 16 (9) 3 (6.8)
Drug registry 61 (34.5) 3 (6.8)
I do not know 28 (15.8) 28 (63.7)
If I report ADR I am afraid it will impact my 
relationships with drug manufacturer
Yes 7 (4.7) 2 (4.5) 0.126 0.7223
No 141 (95.3) 42 (95.5)
One ADR reported will not be noticed and does not 
have importance
Agree 19 (12.8) 7 (15.9) 0.0739 0.7858
Disagree 129 (87.2) 37 (84.1)
Patients never mention any ADR
Agree 33 (22.3) 2 (4.5) 6.029 0.0141*
Disagree 115 (77.7) 42 (95.5)
Known ADR should not be reported again
Agree 47 (31.8) 18 (40.9) 1.247 0.2642
Disagree 101 (68.2) 26 (59.1)
I do not have enough clinical knowledge to 
recognize ADR that should be reported
Agree 44 (29.7) 9 (20.5) 1.558 0.2120
Disagree 104 (70.3) 35 (79.5)
*Statistically significant, ADR=Adverse drug reaction
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by the physicians in Great Britain (19), the 
Netherlands (20), and Spain (21). Our findings 
suggest that the low rate of ADR reporting still per-
sists, since the majority of the respondents (85% of 
the pharmacists and 73% of the physicians) did not 
report any ADR in 2014  year. A  study published 
in 2010 examined current ADR reporting practices 
among different South Eastern European countries. 
They concluded that health care professionals from 
Bosnia and Herzegovina had the lowest response 
rate to the questionnaires sent (22). A  study from 
Serbia, a neighboring country to Bosnia and 
Herzegovina, published in 2010, also showed a low 
rate of hospital ADR reporting in Serbia in com-
parison to other countries (23). The results of a sur-
vey on hospital pharmacists’ services conducted by 
the European Association of Hospital Pharmacists, 
showed a low rate of ADR related services in Bosnia 
and Herzegovina (24). The situation in Croatia is 
much better, since the ADR reporting is continuous 
and well recorded (25).
Our sample was heterogeneous and we identified 
significant differences among the pharmacist and 
physician groups in terms of the number of respon-
dents. However, there was no significant difference 
in terms of working experience that could impact 
the attitudes and practice in ADR reporting. The 
majority of the respondents from both groups 
agreed that ADR reporting is a legal, professional, 
as well as ethical obligation. A significant difference 
was observed between the respondents with regard 
to whose obligation is ADR reporting. The pharma-
cists considered that they have the primary respon-
sibility, while the physicians considered the same 
for themselves. This could be a consequence of low 
cooperation and communication between these two 
groups of health care professionals. Several studies 
reported physicians’ attitudes towards the roles and 
responsibilities of community pharmacists (26,27). 
In our study, the respondents from both groups 
disagreed that consulting a pharmacist or physi-
cian before reporting ADRs should be performed. 
Seventy-four percent of the pharmacists and 77% of 
the physicians reported these answers. Although the 
ADR reporting rate is very low, in this study, both 
the pharmacists (76%) and physicians (78%) stated 
that ADRs should be reported to the ALIMSBIH. 
In addition, a significant number of them stated 
that ADRs should be reported to the manufac-
turer of the drug or other organizations. Although 
TABLE 4. Potential factors influencing improvements in ADR reporting
Potential factors influencing improvements in 
ADR reporting
Pharmacists Physicians Chi‑square Significance 
level (p)
ADR reporting should be recognized by 
professional chambers
Agree 66 10 9.901 0.0017*
Disagree 82 34
ADR reporting procedure should be simplified
Agree 123 44 7.119 0.0076*
Disagree 25 0
ADR reporting should be paid
Agree 27 14 2.96 0.0855
Disagree 121 30
ADR reporting should be possible by
Telephone 28 6 3.205 0.2014
Written and signed form 68 22
Internet (e‑reporting) 89 15
I need additional education about ADR reporting
Yes 81 29 1.306 0.2532
No 67 15
*Statistically significant, ADR=Adverse drug reaction
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previously published studies have shown positive 
health care professionals’ attitudes to ADR report-
ing (28), in this study we tried to identify the most 
common barriers to ADR reporting. A significant 
difference among the two groups was observed with 
respect to two barriers to reporting ADRs, lack of 
knowledge of whom to report and where to find an 
ADR reporting form. The main difference between 
the groups was that the pharmacists were mostly 
concerned about making a wrong report, which 
could cause personal discrediting (21%), as well as 
concerned about exposing themselves (15%). The 
main barrier for the physicians (38%) was lack of 
information on whom to report ADR. Both, the 
pharmacists and physicians, similarly perceived 
lack of knowledge of ADR reporting procedure 
as a barrier. A study performed among health care 
professionals in Northern Cyprus, found that the 
main barrier was lack of knowledge of this practice. 
They recommended additional education in order 
to increase ADR reporting in their country (29). 
A  study on the role of pharmacists in pharma-
covigilance, conducted among Turkish community 
pharmacists, showed that the pharmacists consid-
ered their role in ADR reporting essential, even 
though the ADR reporting was very low. Similar 
to our results, in their study, the main reason for 
underreporting was also insufficient knowledge of 
pharmacovigilance (30).
The two groups in our study answered differently 
where to find the ADR reporting form. The majority 
of the pharmacists reported that an ADR reporting 
form could be found at ALIMSBiH website (41%), 
as well as a part of Drug registry (34%), a publica-
tion issued annually by the ALIMSBiH. On con-
trary, for the physicians, the main barrier was that 
they did not know where to find an ADR reporting 
form (64%). This discrepancy could be explained by 
the fact that the Drug registry is obligatory literature 
in each pharmacy by law, so pharmacists are more 
familiar with the content of this publication.
Regarding the questions related to possible improve-
ments, the two groups showed different attitudes to 
whether ADR reporting should be evaluated as a 
part of continuing education, and recognized by the 
professional chambers. The pharmacists considered 
that this should be the case, while the physicians did 
not. Both groups agreed that the procedure should 
be simplified, which is in line with previous find-
ings (31). Online ADR reporting is one of the ways 
how to increase the reporting rate, and this was 
mainly proposed by the pharmacists (47%). In addi-
tion, both groups proposed the written form as the 
means to perform ADR reporting. The respondents 
from both groups agreed that additional education 
in ADR reporting would be useful (55% of the phar-
macists and 66% of the physicians). This should be 
a clear indication to the ALIMSBiH to popular-
ize ADR reporting through additional education, 
training, and to inform the health care professionals 
about this issue. Some studies suggest that even the 
introduction of pharmacovigilance-related course 
in undergraduate programs could improve ADR 
reporting, since this would allow for future health 
care professionals to understand the importance 
of this system (32). It is also important to develop 
new competencies for the pharmacists in order to 
improve their role in a health care system and move 
the perception from a medicines dispenser to phar-
maceutical care provider (33). This should also be 
incorporated into undergraduate and postgraduate 
curricula in order to prepare future pharmacists to 
be able to respond to new challenges in labor mar-
kets and health care activities.
The main limitation of this study was a significantly 
lower number of physicians who participated. 
Additionally, the study did not cover health care 
professionals from the entire country. Nevertheless, 
this is the first study that compared the attitudes 
of pharmacists and physicians to ADR report-
ing and pharmacovigilance system in Bosnia and 
Herzegovina.
CONCLUSION
ADR reporting is still in focus, and underreport-
ing is an issue in many countries in the world. 
Although ADR reporting is established in Bosnia 
and Herzegovina through the ALIMSBIH, the 
reporting rate is still low compared to the neighbor-
ing as well as developed countries. Pharmacists and 
physicians, as most accessible health care profession-
als at the primary health care level, play important 
roles in this process. This study confirmed a positive 
attitude by these two groups of health care profes-
sionals towards the importance of ADR reporting, 
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but also showed different levels of knowledge of this 
process. We identified different barriers to the ADR 
reporting among the surveyed professionals, as well 
as significant improvement measures, like additional 
education, that could be performed in Bosnia and 
Herzegovina. Further investigations should be per-
formed among a larger number of health care pro-
fessionals in order to identify precise problems and 
obstacles, as well as to improve this practice through 
additional education.
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